Cardiac monitoring systems can continuously monitor a patient's electrocardiogram (ECG) signal to generate a rhythm classification. Because the ECG signals can be a mixture of multiple different QRS morphologies, using only heart rate (HR) and HR variability can produce incorrect heart rhythm classification, especially in classifying supraventricular tachycardia (SVT) rhythms. For example, atrial fibrillation (AF) and SVT rhythms can have high HR variability, so a cardiac monitoring system may have difficulty distinguishing between AF and SVT rhythms if only HR variability is used. A noisy ECG signal can increase the difficulty. Existing rhythm methods based on RR interval variability may have a high percentage of AF false positive alarms due to noise, PR interval variability, premature ventricular contractions (PVCs), and premature atrial contractions (PACs).
Claimed subject matter is particularly pointed out and distinctly claimed in the concluding portion of the specification. However, such subject matter may be understood by reference to the following detailed description when read with the accompanying drawings in which:
It will be appreciated that for simplicity and/or clarity of illustration, elements illustrated in the figures have not necessarily been drawn to scale. For example, the dimensions of some of the elements may be exaggerated relative to other elements for clarity. Further, if considered appropriate, reference numerals have been repeated among the figures to indicate corresponding and/or analogous elements.
In the following detailed description, numerous specific details are set forth to provide a thorough understanding of claimed subject matter. It will, however, be understood by those skilled in the art that claimed subject matter may be practiced without these specific details. In other instances, well-known methods, procedures, components and/or circuits have not been described in detail.
In the following description and/or claims, the terms coupled and/or connected, along with their derivatives, may be used. In particular embodiments, connected may be used to indicate that two or more elements are in direct physical and/or electrical contact with each other. Coupled may mean that two or more elements are in direct physical and/or electrical contact. However, coupled may also mean that two or more elements may not be in direct contact with each other, but yet may still cooperate and/or interact with each other. For example, “coupled” may mean that two or more elements do not contact each other but are indirectly joined together via another element or intermediate elements. Finally, the terms “on,” “overlying,” and “over” may be used in the following description and claims. “On,” “overlying,” and “over” may be used to indicate that two or more elements are in direct physical contact with each other. It should be noted, however, that “over” may also mean that two or more elements are not in direct contact with each other. For example, “over” may mean that one element is above another element but not contact each other and may have another element or elements in between the two elements. Furthermore, the term “and/or” may mean “and”, it may mean “or”, it may mean “exclusive-or”, it may mean “one”, it may mean “some, but not all”, it may mean “neither”, and/or it may mean “both”, although the scope of claimed subject matter is not limited in this respect. In the following description and/or claims, the terms “comprise” and “include,” along with their derivatives, may be used and are intended as synonyms for each other.
Referring now to
In example shown in
In some examples, differential vectors can be formed by subtracting two digitized ECG signals. ECG rhythm analysis then can be performed on these four vectors. Vectors E12, E13, E34, and E24 are the differential vectors that are derived from the single-ended vectors. Such differential vectors may include, for example, vector (E24) 132, vector (E34) 134, vector (E12) 136, and vector (E13) 138. The defibrillator shock vector 140 may be generated between the anterior defibrillation pad 104 and the posterior defibrillation pad 108. The ECG analysis algorithm includes provisions for excluding vectors that have noise or when a leads-off condition or situation is detected. Monitoring four vectors rather than monitoring two vectors is believed to contribute to enhanced ECG signal analysis and processing of the shock application algorithm to reduce the number of false shock events.
In one or more embodiments, the signals from four ECG electrodes can be combined to form six different vectors. In some embodiments, an ECG monitoring device can use four vectors for QRS complex analysis or heart rate analysis to determine if a shock should be applied. In some examples, a WCD device can be capable of performing the analysis and shock application determination if one or more of the vectors is noisy or one or more of the ECG leads is in a lead-off condition wherein the lead is not contacting the patient's skin or is not sufficiently contacting the patient's skin to allow an ECG signal to be obtained with that ECG lead. In some embodiments, three ECG electrodes may be used and three ECG vectors may be analyzed. In other embodiments, five or six ECG vectors may be analyzed using four ECG electrodes. In some embodiments, a single vector is used and analyzed. It should be noted that in general an ECG monitoring device can use and analyze fewer than four vectors or greater than four vectors, and the number of vectors can be increased beyond six vectors by using additional ECG electrodes, and the scope of the disclosed subject matter is not limited in this respect. In some examples, an ECG monitoring device can use four channels out of six possible differential channels formed from four independent electrodes placed around the chest of a patient 110. In other embodiments, a different number of channels, including only one channel, can be used. In embodiments where the ECG monitoring device comprises a WCM, a different number of electrodes can be used, often a reduced number of electrodes, or a different garment system can be used other than the garment or support structure 112 shown in
In the example shown in
In some embodiments a cardiac monitoring device using the ECG electrodes as shown in
According to some embodiments, a cardiac monitoring system or device such as a Wearable Cardioverter Defibrillator (WCD) or a Wearable Cardiac Monitor (WCM) is configured to continuously monitor the patient's ECG signal and generate a rhythm discrimination. In some embodiments the cardiac monitoring device can be configured to detect similar QRS complexes and their P-waves to identify the QRS complexes that are normally conducted through the AV node, referred to herein as normally conducted QRS complexes, and distinguish between different types of SVT. Because the ECG signals can be a mixture of multiple different QRS morphologies and noise, normally conducted QRS complex identification and RR interval and P-wave analysis is used to determine the rhythms more accurately, including classifying SVT rhythms, in accordance with one or more embodiments.
According to some embodiments, a cardiac monitoring device such as a WCD or a WCM can be configured to continuously monitor the patient's ECG signal and detect normally conducted QRS complexes. For arrhythmias with HR in the VT zone, detecting normally conducted QRS complexes can be used to distinguish supraventricular-originated arrhythmias such as AF or SVT from ventricular-originated arrhythmias such as VT or VF. In some embodiments, the normally conducted QRS complexes can be detected by detecting similar QRS complexes. In some embodiments, QRS similarity can be detected by formulating a template of normally conducted QRS complexes and determining a correlation between the formulated template and detected QRS complexes. In other embodiments, QRS similarity can be determined using other approaches, for example comparing the width and amplitude of the QRS complexes. The accuracy of the rhythm analysis can be affected by noise, so analyzing noisy QRS complexes can increase false alarms of the rhythm classification. By analyzing similar QRS complexes as is done in embodiments discussed herein, noise effects can be reduced because noise would tend to make QRS complexes less similar. This in turn tends to increase the accuracy of the rhythm classification and reduce false positives.
Furthermore, normally conducted QRS arrhythmias are not shockable rhythms for a WCD. It is possible that if a conventional WCD mistakenly diagnoses a normally conducted QRS rhythm as a shockable rhythm, it would provide an unnecessary and potentially dangerous shock to the patient.
In addition, as described below, for detected supraventricular-originated arrhythmias, meaning those with normally conducted QRS complexes, the RR interval between consecutive normally conducted QRS complexes and the morphology of their P-waves can be analyzed to classify the rhythm into AF or various SVT rhythms, in some embodiments.
In some embodiments, the cardiac monitoring system can be used in other types of external monitoring devices, for example non-wearable external defibrillators such as those used by emergency medical technicians (EMTs), automated external defibrillators (AEDs), and hospital defibrillators, or in implanted devices. The cardiac monitoring system of such embodiments may be deployed where monitored patients are being transported and causing movement between the ECG sensors and the portion of the patient that the sensors contact or are in high EMI environments, which can introduce noise to the patient's ECG.
Referring now to
The processor 216 processes the digital ECG data received from the preamplifier 210 with one or more digital filters 218. Since the preamplifier 210 has a wide dynamic range that is much wider than the amplitude range of the ECG signals, digital filters 218 can be utilized to process the ECG data without concern for clipping the incoming signals. One of the digital filters 218 can include a matched filter to facilitate identification of QRS pulses in the incoming data stream. The wide dynamic range of the preamplifier 210 allows at least most of the ECG filtering to happen in software without the signal being clipped. Digital filters 218 can be very effective at removing artifacts from the ECG data. In some examples, digital filters 218 can include one or more bandpass filters to filter the ECG data as discussed in further detail below.
In some examples, the processor 216 can apply a rhythm analysis algorithm (RAA) 220 using QRS width information and heart rate data extracted from the digital ECG data using a segment-based processing analysis and the QRS width versus heart rate analysis to make a shock or no-shock determination. In some embodiments, segment-based processing analysis can be performed as described in US 2019/0030351 A1 “Wearable Cardioverter Defibrillator (WCD) System Reacting to High-Frequency ECG Noise”. Said US 2019/0030351 A1 is hereby incorporated herein in its entirety. The RAA 220 receives the digitized ECG signal and calculates the heart rate and QRS width for each segment. The digitized ECG signal is passed over the isolation barrier 214, and the heart rate is derived from the digitized ECG signal. The heart rate and QRS width can be used for making a shock/no-shock decision for each segment, which then can lead to an alarm and a shock. In the event a shockable event is identified, the processor 216 will open a tachycardia episode to start the shock process. Unless the patient 110 provides a patient response using the stop button 222 or other user interface to send a stop shock signal to the processor 216 to intervene before the shock is applied, the processor 216 can send a shock signal to the high voltage subsystem 224 which will apply a defibrillation voltage across the defib front electrode 104 and the defib back electrode 108 to apply one or more therapeutic shocks. In embodiments, the system will provide such shocks until there is no longer any shockable event (VT or VF), or until the energy in a battery or capacitor of high voltage subsystem 224 is depleted or after a predetermined number of shocks have been delivered.
In one or more embodiments of WCD 200, the digital filters 218 coupled with the wide dynamic range of the preamplifier 210 can allow analysis of signals that otherwise would be clipped in systems with a more limited dynamic range. In addition, the matched filter of the digital filters 218 preferentially highlights complexes similar to the patient's normal rhythm. As a result, artifacts that otherwise may be difficult to discriminate using other methods may be significantly attenuated by the matched filter to identify QRS complexes.
It should be noted that a subset of the elements of the WCD 200 of
Referring now to
Referring now to
In some embodiments, the ECG or cardiac monitoring device can comprise a wearable cardioverter defibrillator such as WCD 200 having multiple ECG vectors from multiple electrodes for monitoring the patient 110. In some embodiments, a template of the selected channel can be formulated using method 400, and AF can be detected as described with respect to
At operation 410, bandpass filtered ECG signals can be collected for a fixed duration. As an example, the bandpass filter may have a bandwidth of about 8 Hz to about 25 Hz, and the fixed duration can be 60 seconds. At operation 412, a QRS detector can be applied to the filtered ECG signal to identify locations of QRS complexes in the ECG signal. Any suitable QRS detector can be used, for example, a QRS detector as disclosed in published US patent application US 2018/0093102 A1 titled WEARABLE CARDIOVERTER DEFIBRILLATOR (WCD) WITH POWER-SAVING FUNCTION. Said published application US2018/0093102 A1 is hereby incorporated herein in its entirety. At operation 414, for each QRS complex the location of the minimum value can be identified as the fiducial point in a window, for example 160 ms starting from the detection point. For example, the minimum value can be the minimum value 310 shown in
At operation 416, the first QRS complex waveform can be set as the first template, and the template count can be set to a value of one (template count=1). In some examples, if there is an existing template, the existing template optionally can be the starting template with a template count of one. At operation 418, the next QRS complex waveform can be compared to the existing template waveform. The concept is to identify similar QRS complexes. If the next QRS complex does not match or is not correlated with the existing template or any template as determined at decision block 420, then the method continues by comparing the next QRS complex to the template. If the current QRS complex is not correlated to any templates, then this QRS complex can be used as a new template by adding this QRS complex as a new template at operation 428. The size or number of the templates can increase as more uncorrelated QRS complexes are detected. If the next QRS complex waveform is correlated with the existing template as determined at decision block 420, the existing template can be updated at block 422, and the template count can be incremented by one. The current QRS complex can be correlated to multiple templates, and the count of each of the templates can increase by one for each match. Optionally, in some embodiments, a comparison can be made with the fiducial points 310 to determine fiducial point shift, for example a minimum point −2 to minimum point +2. The fiducial point with the best match can be selected. In some examples, the correlation decision can be made based on calculation of a feature correlation coefficient (FCC). In other examples, other measures of correlation can be used, for example a sample correlation coefficient (SCC) wherein FCC is a squared version of SCC and the scope of the disclosed subject matter is not limited in this respect. Other measures of correlation or similarity can be utilized, for example comparison of the height and/or or width of the QRS complexes to the template, a normalized area difference method which measures the area difference between the QRS complex and the template divided by the area of the template, a frequency domain analysis method, and so on. As an example, for one dataset {x1, . . . , xn} containing n values and another dataset {y1, . . . , yn} containing n values, then that formula for sample correlation coefficient (SCC) r is:
In the equation above, the x data values can correspond to the values of a sampled QRS complex waveform being compared to the template, and the y data values can correspond to the template to which a the QRS complex waveform is being compared, wherein
Updated template=0.9*current template+0.1*current QRS complex
In the above equation, to arrive at the values of the updated template, the values in the current template are each multiplied by 0.9 and the values of the current QRS complex are multiplied by 0.1, then the corresponding values are added to arrive at the values for the updated template. It should be noted that although weighting multipliers 0.9 and 0.1 in the above example can be used for some embodiments, other values of multipliers can be used in other embodiments, for example 0.8 and 0.2 or 0.95 and 0.005, and so on, and the scope of the disclosed subject matter is not limited in this respect. At operation 424, QRS complexes can continue to be compared to the existing template until all QRS complexes have been compared and all templates have a template count value. The template having the highest template count, meaning the most similarity to the greatest number of the QRS complexes in a given segment of QRS complexes, can be selected at operation 426 to be the main template. If the highest template count is more than 50 percent of the number of detected QRS complexes in the segment, then the main template is selected as the main template of this segment. Otherwise, the segment can be considered to be an unstable situation and therefore the segment can be skipped. The main template can then be used to identify normally conducted QRS complexes to detect AF using RR intervals in the normally conducted QRS complexes according to
Referring now
Referring now to
At operation 610, the main template can be applied to each QRS complex in a given segment of QRS complexes. The FCC values of each of the QRS complexes can then be calculated, or alternatively SCC values can be calculated in some embodiments. At operation 612, if the FCC value (or SCC value) for a QRS complex is greater than 0.9 or some threshold, then that QRS complex can be considered as a normally conducted QRS complex, and can be labeled as a supraventricular (SV) complex, meaning that the QRS complex is a normally conducted QRS complex that originate above the sinoatrial (SA) node. It should be noted that although an FCC value (or an SCC value) of 0.9 can be used as a matching or correlation threshold as an example, other values for the FCC or SCC can be used as a threshold, and the scope of the disclosed subject matter is not limited in this respect. For example, an FCC range of 0.8 to 0.9 can be used, and an SCC range of 0.9 to 0.95 can be used. At operation 614, the RR intervals 518 between consecutive SV complexes can be calculated, and the RR intervals can be labeled as SV RR intervals. It should be noted that QRS complexes having FCC values (or SCC) values below the threshold, such as having value below 0.9, are disregarded since such uncorrelated QRS complexes can be considered as not being normally conducted QRS complexes or otherwise are noisy.
At operation 616, the highest 25 percent of RR intervals in the ECG segment can be identified. In some embodiments, this threshold can range from about 20 percent to about 30 percent, and the scope of the disclosed subject matter is not limited in this respect. At operation 618, for each identified RR interval, the atrial waveform can be saved in a window between 260 ms and 120 ms from the fiducial point of the second SV complex of an RR interval. In some embodiments, the window can be defined to have a range large enough to capture the P-waves along with the QRS complexes. At operation 620, the P-wave range can be measured during normal sinus rhythm (NSR) and saved as described above to be used later for SVT rhythm classification.
Referring now to
High heart rate (HR) variability has been observed in AF and in other SVT rhythms, so HR variability alone is not used to classify the rhythm in some embodiments. For example, the rhythm shown in
Referring now to
In some embodiments, at operation 912 an atrial template can be formulated for example using the template formation method 400 of
At operation 922, if the atrial template waveforms are similar, then the rhythm can be classified as not AF. In some embodiments, this rhythm can be an SVT rhythm such as premature atrial contraction (PAC). In other embodiments, the atrial waveforms can be compared to a stored P-wave from a normal sinus rhythm (NSR) at operation 924. If the atrial waveform is similar to the P-wave, then the rhythm can be classified as a sinus rhythm with varying RP intervals at operation 926.
Referring now to
Referring now to
Although the claimed subject matter has been described with a certain degree of particularity, it should be recognized that elements thereof may be altered by persons skilled in the art without departing from the spirit and/or scope of claimed subject matter. It is believed that the subject matter pertaining to a cardiac monitoring system with supraventricular tachycardia (SVT) classifications and many of its attendant utilities will be understood by the forgoing description, and it will be apparent that various changes may be made in the form, construction and/or arrangement of the components thereof without departing from the scope and/or spirit of the claimed subject matter or without sacrificing all of its material advantages, the form herein before described being merely an explanatory embodiment thereof, and/or further without providing substantial change thereto. It is the intention of the claims to encompass and/or include such changes.
The present application is a continuation of U.S. application Ser. No. 17/000,496 (C00003614.USU2) filed Aug. 24, 2020, now U.S. Pat. No. 11,730,418. Said application Ser. No. 17/000,496 claims the benefit of U.S. Provisional Application No. 62/890,313 (C00003612.USP1) filed Aug. 22, 2019 and the benefit of U.S. Provisional Application No. 62/891,216 (C00003614.USP1) filed Aug. 23, 2019. Said application Ser. No. 17/000,496, said Application No. 62/890,313 and said Application No. 62/891,216 are hereby incorporated herein by reference in their entireties.
Number | Name | Date | Kind |
---|---|---|---|
3724455 | Unger | Apr 1973 | A |
4583524 | Hutchins | Apr 1986 | A |
4619265 | Morgan et al. | Oct 1986 | A |
4666432 | McNeish et al. | May 1987 | A |
4698848 | Buckley | Oct 1987 | A |
4928690 | Heilman et al. | May 1990 | A |
4955381 | Way et al. | Sep 1990 | A |
5078134 | Heilman et al. | Jan 1992 | A |
5228449 | Christ et al. | Jul 1993 | A |
5348008 | Bornn et al. | Sep 1994 | A |
5353793 | Bornn | Oct 1994 | A |
RE34800 | Hutchins | Nov 1994 | E |
5394892 | Kenny et al. | Mar 1995 | A |
5405362 | Kramer et al. | Apr 1995 | A |
5474574 | Payne et al. | Dec 1995 | A |
5618208 | Crouse et al. | Apr 1997 | A |
5662690 | Cole et al. | Sep 1997 | A |
5708978 | Johnsrud | Jan 1998 | A |
5741306 | Glegyak et al. | Apr 1998 | A |
5782878 | Morgan et al. | Jul 1998 | A |
5792204 | Snell | Aug 1998 | A |
5902249 | Lyster | May 1999 | A |
5913685 | Hutchins | Jun 1999 | A |
5944669 | Kaib | Aug 1999 | A |
6047203 | Sackner et al. | Apr 2000 | A |
6065154 | Hulings et al. | May 2000 | A |
6108197 | Janik | Aug 2000 | A |
6148233 | Owen et al. | Nov 2000 | A |
6201992 | Freeman | Mar 2001 | B1 |
6263238 | Brewer et al. | Jul 2001 | B1 |
6280461 | Glegyak et al. | Aug 2001 | B1 |
6287328 | Snyder et al. | Sep 2001 | B1 |
6304780 | Owen et al. | Oct 2001 | B1 |
6319011 | Motti et al. | Nov 2001 | B1 |
6334070 | Nova et al. | Dec 2001 | B1 |
6356785 | Snyder et al. | Mar 2002 | B1 |
6427083 | Owen et al. | Jul 2002 | B1 |
6450942 | Lapanashvili et al. | Sep 2002 | B1 |
6529875 | Nakajima et al. | Mar 2003 | B1 |
6546285 | Owen et al. | Apr 2003 | B1 |
6597943 | Taha et al. | Jul 2003 | B2 |
6671545 | Fincke | Dec 2003 | B2 |
6681003 | Linder et al. | Jan 2004 | B2 |
6762917 | Verbiest et al. | Jul 2004 | B1 |
7065401 | Worden | Jun 2006 | B2 |
7099715 | Korzinov et al. | Aug 2006 | B2 |
7212850 | Prystowsky et al. | May 2007 | B2 |
7559902 | Ting et al. | Jul 2009 | B2 |
7587237 | Korzinov et al. | Sep 2009 | B2 |
7865238 | Brink | Jan 2011 | B2 |
7870761 | Valentine et al. | Jan 2011 | B2 |
7907996 | Prystowsky et al. | Mar 2011 | B2 |
7941207 | Korzinov | May 2011 | B2 |
7974689 | Volpe et al. | Jul 2011 | B2 |
8135462 | Owen et al. | Mar 2012 | B2 |
8140154 | Donnelly et al. | Mar 2012 | B2 |
8369944 | Macho et al. | Feb 2013 | B2 |
8527028 | Kurzweil et al. | Sep 2013 | B2 |
8548557 | Garstka et al. | Oct 2013 | B2 |
8560044 | Kurzweil et al. | Oct 2013 | B2 |
8615295 | Savage et al. | Dec 2013 | B2 |
8644925 | Volpe et al. | Feb 2014 | B2 |
8676313 | Volpe et al. | Mar 2014 | B2 |
8706255 | Phillips et al. | Apr 2014 | B2 |
8742349 | Urbon et al. | Jun 2014 | B2 |
8897860 | Volpe et al. | Nov 2014 | B2 |
8904214 | Volpe et al. | Dec 2014 | B2 |
8965500 | Macho et al. | Feb 2015 | B2 |
9008801 | Kaib et al. | Apr 2015 | B2 |
9084583 | Mazar et al. | Jul 2015 | B2 |
9089685 | Sullivan et al. | Jul 2015 | B2 |
9119547 | Cazares et al. | Sep 2015 | B2 |
9131901 | Volpe et al. | Sep 2015 | B2 |
9132267 | Kaib | Sep 2015 | B2 |
9265432 | Warren et al. | Feb 2016 | B2 |
9314210 | Li | Apr 2016 | B2 |
9345898 | Piha et al. | May 2016 | B2 |
9408548 | Volpe et al. | Aug 2016 | B2 |
9445719 | Libbus et al. | Sep 2016 | B2 |
9454219 | Volpe et al. | Sep 2016 | B2 |
9579020 | Libbus et al. | Feb 2017 | B2 |
9591986 | Maskara et al. | Mar 2017 | B2 |
9592403 | Sullivan | Mar 2017 | B2 |
9598799 | Shoshani et al. | Mar 2017 | B2 |
9655537 | Bardy et al. | May 2017 | B2 |
9675804 | Whiting et al. | Jun 2017 | B2 |
9724008 | Sullivan et al. | Aug 2017 | B2 |
9826911 | Fu et al. | Nov 2017 | B2 |
9878171 | Kaib | Jan 2018 | B2 |
9895105 | Romem | Feb 2018 | B2 |
9901741 | Chapman et al. | Feb 2018 | B2 |
9907477 | Quan et al. | Mar 2018 | B2 |
9955887 | Hughes et al. | May 2018 | B2 |
9999368 | Perschbacher et al. | Jun 2018 | B2 |
RE46926 | Bly et al. | Jul 2018 | E |
10016143 | Siejko | Jul 2018 | B2 |
10016613 | Kavounas | Jul 2018 | B2 |
10039469 | Higgins et al. | Aug 2018 | B2 |
10045710 | Higgins et al. | Aug 2018 | B2 |
10076656 | Dar et al. | Sep 2018 | B2 |
10307133 | Kaib | Jun 2019 | B2 |
10463867 | Kaib et al. | Nov 2019 | B2 |
10589110 | Oskin et al. | Mar 2020 | B2 |
10599814 | Landrum et al. | Mar 2020 | B2 |
11730418 | Kim | Aug 2023 | B2 |
20010056245 | Mlynash et al. | Dec 2001 | A1 |
20020181680 | Linder et al. | Dec 2002 | A1 |
20030144700 | Brown et al. | Jul 2003 | A1 |
20030158593 | Heilman et al. | Aug 2003 | A1 |
20040059327 | Jenkins et al. | Mar 2004 | A1 |
20040111120 | Sarkar et al. | Jun 2004 | A1 |
20040243014 | Lee et al. | Dec 2004 | A1 |
20050107833 | Freeman et al. | May 2005 | A1 |
20050107834 | Freeman et al. | May 2005 | A1 |
20060173499 | Hampton et al. | Aug 2006 | A1 |
20060217621 | Kim et al. | Sep 2006 | A1 |
20080312709 | Volpe et al. | Dec 2008 | A1 |
20090005827 | Weintraub et al. | Jan 2009 | A1 |
20090275849 | Stewart | Nov 2009 | A1 |
20100007413 | Herleikson et al. | Jan 2010 | A1 |
20100298899 | Donnelly et al. | Nov 2010 | A1 |
20110022105 | Owen et al. | Jan 2011 | A9 |
20110288604 | Kaib et al. | Nov 2011 | A1 |
20110288605 | Kaib et al. | Nov 2011 | A1 |
20120150008 | Lanar et al. | Jan 2012 | A1 |
20120112903 | Kaib et al. | May 2012 | A1 |
20120144551 | Guldalian | Jun 2012 | A1 |
20120158075 | Kaib et al. | Jun 2012 | A1 |
20120191476 | Reid et al. | Jul 2012 | A1 |
20120265265 | Razavi et al. | Oct 2012 | A1 |
20120283794 | Kaib et al. | Nov 2012 | A1 |
20120293323 | Kaib et al. | Nov 2012 | A1 |
20120302860 | Volpe et al. | Nov 2012 | A1 |
20120310315 | Savage et al. | Dec 2012 | A1 |
20130085538 | Volpe et al. | Apr 2013 | A1 |
20130144355 | Macho et al. | Jun 2013 | A1 |
20130231711 | Kaib | Sep 2013 | A1 |
20130245388 | Rafferty et al. | Sep 2013 | A1 |
20130274565 | Langer et al. | Oct 2013 | A1 |
20130317852 | Worrell et al. | Nov 2013 | A1 |
20130325078 | Whiting et al. | Dec 2013 | A1 |
20140012144 | Crone | Jan 2014 | A1 |
20140025131 | Sullivan et al. | Jan 2014 | A1 |
20140046391 | Cowan et al. | Feb 2014 | A1 |
20140070957 | Longinotti-Buitoni et al. | Mar 2014 | A1 |
20140163663 | Poddar et al. | Jun 2014 | A1 |
20140324112 | Macho et al. | Oct 2014 | A1 |
20140378812 | Saroka et al. | Dec 2014 | A1 |
20150039053 | Kaib et al. | Feb 2015 | A1 |
20150297135 | Shoshani et al. | Oct 2015 | A1 |
20150328472 | Sullivan et al. | Nov 2015 | A1 |
20160004831 | Carlson et al. | Jan 2016 | A1 |
20160082277 | Foshee, Jr. et al. | Mar 2016 | A1 |
20160113581 | Amir et al. | Apr 2016 | A1 |
20160256104 | Romem et al. | Sep 2016 | A1 |
20160283900 | Johnson et al. | Sep 2016 | A1 |
20170014073 | Shoshani et al. | Jan 2017 | A1 |
20170027469 | Amir et al. | Feb 2017 | A1 |
20170036066 | Chahine | Feb 2017 | A1 |
20170040758 | Amir et al. | Feb 2017 | A1 |
20170162840 | Pendry | Jun 2017 | A1 |
20170296076 | Mahajan et al. | Oct 2017 | A1 |
20170319862 | Foshee, Jr. et al. | Nov 2017 | A1 |
20170367591 | Jorgenson | Dec 2017 | A1 |
20180116537 | Sullivan et al. | May 2018 | A1 |
20180117299 | Gustavson et al. | May 2018 | A1 |
20180184933 | Sullivan et al. | Jul 2018 | A1 |
20180185662 | Foshee, Jr. et al. | Jul 2018 | A1 |
20180243578 | Volosin | Aug 2018 | A1 |
20180361165 | Jaax et al. | Dec 2018 | A1 |
20190030352 | Sullivan et al. | Jan 2019 | A1 |
20190076666 | Medema | Mar 2019 | A1 |
20190116896 | Armour et al. | Apr 2019 | A1 |
20190117099 | Bardy | Apr 2019 | A1 |
20190159733 | Shusterman | May 2019 | A1 |
20190321650 | Raymond et al. | Oct 2019 | A1 |
20190336026 | Dawoud et al. | Nov 2019 | A1 |
Number | Date | Country |
---|---|---|
102005060985 | Jun 2007 | DE |
2305110 | Apr 2011 | EP |
4320257 | Aug 2009 | JP |
2014526282 | Oct 2014 | JP |
5963767 | Aug 2016 | JP |
9839061 | Sep 1998 | WO |
2011146448 | Nov 2011 | WO |
2012064604 | May 2012 | WO |
2012151160 | Nov 2012 | WO |
2015056262 | Apr 2015 | WO |
Entry |
---|
Heartstart MRx and XL AED Algorithm—Application Note, Jul. 2001, Edition 2 Philips Healthcare, USA. |
International Search Report and Written Opinion for PCT Application No. PCT/US2015/051726, dated May 20, 2016, European Patent Office, Rijswijk, 11 pages. |
Klein, H. U., Goldenberg I., & Moss, A. J., Risk Stratification for Implantable Cardioverter Defibrillator Therapy: The Role of the Wearable Cardioverter-Defibrillator, Clinical update, European Heart Journal, May 31, 2013, pp. 1-14, doi:10.1093/eurheartj/eht167, European Society of Cardiology. |
Lifecor LifeVest System Model WCD 3100 Operator's Manual, 2006, PN 20B0040 Rev FI, Zoll Lifecor Corporation, Pittsburgh, PA. |
LifeVest Model 4000 Patient Manual, Zoll, 2009, PN 20B0047 Rev B. |
Pagan-Carlo, et al., “Encircling Overlapping Multipulse Shock Waveforms for Transthoracic Defibrillation,” JACC Journals, Dec. 1998, vol. 32 Issue 7, p. 2065-2071. |
Zoll, LifeVest, Proven protection from Sudden Cardiac Death, issued Mar. 27, 2018, 4 pages. Pittsburgh PA, USA. |
Number | Date | Country | |
---|---|---|---|
20230397874 A1 | Dec 2023 | US |
Number | Date | Country | |
---|---|---|---|
62891216 | Aug 2019 | US | |
62890313 | Aug 2019 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 17000496 | Aug 2020 | US |
Child | 18236645 | US |